SUBSCRIBE
SUBSCRIBE

Janssen Pharmaceutical Inc.

NEWS
Business
Achillion Slashes Staff and Initiates Restructuring Following Termination of J&J Deal
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.
February 22, 2018
 · 
2 min read
 · 
Alex Keown
J&J Terminates RA and Leukemia Drug From Pipeline
Business
Could J&J’s Deal With Theravance Develop a Replacement for Remicade in IBD?
Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection.
February 21, 2018
 · 
2 min read
 · 
Alex Keown
FDA
J&J Wins FDA Nod for Erleada, the First Drug for Nonmetastatic Prostate Cancer
Janssen got a little love from the FDA on Wednesday.
February 14, 2018
 · 
3 min read
 · 
Alex Keown
Business
J&J Gambles $1B on Theravance and Its GI Pipeline
J&J inked a global collaboration deal with Theravance Biopharma to develop a drug for IBD.
February 7, 2018
 · 
2 min read
 · 
Mark Terry
J&J Terminates RA and Leukemia Drug From Pipeline
Business
Little Idorsia Scores $230M+ R&D Deal With Johnson & Johnson
Today, Janssen Biotech announced it had exercised its option to enter into a collaboration deal with Idorsia to jointly develop and market aprocitentan and any derivative compounds.
December 4, 2017
 · 
2 min read
 · 
Mark Terry
Arcturus co-founders Padmanabh “Pad” Chivukula and
Business
Arcturus Rockets on New Hep B RNA Deal With Johnson & Johnson
Shares of Arcturus are up nearly 15 percent in Thursday morning trading after the company inked a collaboration agreement with Janssen Pharma to develop a hepatitis B drug program.
October 19, 2017
 · 
2 min read
 · 
Alex Keown
Johnson & Johnson Quits Multibillion-Dollar Hep C Drug Program, Partners' Stocks Fall
Pharm Country
Exclusive: Janssen Pharmaceutical Just Came Clean on Drug Pricing Data
February 28, 2017
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Janssen Pharmaceutical, Medivir Terminate AL-704 Phase I for Treatment of Hepatitis C
December 21, 2015
 · 
2 min read
Biotech Beach
Long-Lasting Flu Vaccine Comes Closer To Reality, The Scripps Research Institute, Janssen Pharmaceutical Reveals
August 26, 2015
 · 
5 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Drug Development
DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
December 1, 2018
 · 
27 min read
Pharm Country
Janssen Shows Commitment to Advancing the Science and Treatment of Blood Cancers and Related Conditions With More Than 80 ASH 2018 Data Presentations From Differentiated Oncology and Cardiovascular Portfolios
November 1, 2018
 · 
43 min read
FDA
U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
October 30, 2018
 · 
14 min read
Drug Development
Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA®▼ (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1
October 30, 2018
 · 
10 min read
Drug Development
Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA® in Treatment-Naïve Adults with HIV-1
October 30, 2018
 · 
14 min read
Janssen’s STELARA® (ustekinumab) demonstrates sustained efficacy in improving clinical remission rates in patients with moderate to severe Crohn’s disease throughout three years
October 24, 2018
 · 
7 min read
Job Trends
Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
October 19, 2018
 · 
11 min read
Policy
Health Canada has approved INVOKANA®* (canagliflozin) for reduction of major adverse cardiovascular events (MACE), the first SGLT2 inhibitor in Canada to receive this indication(1)
October 17, 2018
 · 
8 min read
BioMidwest
Janssen To Highlight Data From Broad Rheumatology Portfolio At The 2018 Annual Meeting Of The American College Of Rheumatology
October 11, 2018
 · 
36 min read
Drug Development
New Phase 3 Data Show Single Dose Of STELARA® (ustekinumab) Induces Clinical Remission And Response In Adults With Moderate To Severe Ulcerative Colitis
October 9, 2018
 · 
15 min read
Load More